Preoperative/neoadjuvant medical therapy for early breast cancer (Q34571913)

3 August 2017

1 reference

title

Preoperative/neoadjuvant medical therapy for early breast cancer (English)

1 reference

3 August 2017

1 reference

I E Smith

1

1 reference

3 August 2017

L Lipton

series ordinal

2

1 reference

3 August 2017

publication date

1 September 2001

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

9

1 reference

3 August 2017

page(s)

561-570

1 reference

Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Multimodal treatment of locoregionally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

A personal experience with Halsted's radical mastectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

1 reference

7 January 2021

Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Preoperative chemotherapy induces apoptosis in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Primary medical therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Primary systemic therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Primary medical (neo-adjuvant) chemotherapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900490-9

7 January 2021

10.1016/S1470-2045(01)00490-9

Identifiers

DOI

1 reference

3 August 2017

1 reference